Scopia Capital Management’s Insys Therapeutics, Inc. INSY Stock Holding History

Scopia Capital Management’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-7,131,221	Closed	-$65.6M	–	44
2016 Q4	$65.6M	Sell	7,131,221 -1,997,792	-22%	-$22.6M	1.24%	24
2016 Q3	$108M	Buy	9,129,013 +141,700	+2%	+$2.15M	1.9%	19
2016 Q2	$116M	Buy	8,987,313 +75,241	+0.8%	+$1.1M	2.4%	18
2016 Q1	$143M	Buy	8,912,072 +3,087,987	+53%	+$58.6M	2.66%	15
2015 Q4	$167M	Buy	5,824,085 +4,105,598	+239%	+$114M	3.31%	9
2015 Q3	$48.9M	Buy	1,718,487 +846,573	+97%	+$31.2M	1.05%	26
2015 Q2	$31.3M	Buy	+871,914	New	+$27.2M	0.61%	27

Other funds holding INSY

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FHAM

Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCP

Fine Capital Partners New York $563M AUM 7.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Scopia Capital Management's INSY Position: Q1 2017 in Review

Scopia Capital Management sold out of Insys Therapeutics, Inc. (INSY) in Q1 2017, closing a stake of 7,131,221 shares — an estimated $65.6M sold.

Scopia Capital Management first reported a position in INSY in Q2 2015 and held it in 7 quarters. The position peaked at $167M in Q4 2015. 116 funds tracked by Wall St. Rank hold INSY as of Q1 2017.

Scopia Capital Management reported no remaining Insys Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
Scopia Capital Management sold 7,131,221 Insys Therapeutics, Inc. shares in Q1 2017, an estimated $65.6M.
Scopia Capital Management first reported a position in Insys Therapeutics, Inc. in Q2 2015 and held it in 7 quarters.
Scopia Capital Management's Insys Therapeutics, Inc. position peaked at $167M in Q4 2015.
116 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2017.

Based on Scopia Capital Management's 13F filing for Q1 2017, filed 15 May 2017.